- Home
- CFR vs HALO Comparison
CFR vs HALO Comparison
Compare CFR & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFR | HALO |
|---|---|---|
| Founded | 1868 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CFR | HALO |
|---|---|---|
| Price | $128.01 | $69.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $137.50 | $73.33 |
| AVG Volume (30 Days) | 412.5K | ★ 2.1M |
| Earning Date | 01-29-2026 | 02-17-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | 20.47 | ★ 56.68 |
| EPS | ★ 9.72 | 4.74 |
| Revenue | ★ $2,141,575,000.00 | $1,242,852,000.00 |
| Revenue This Year | $14.17 | $34.83 |
| Revenue Next Year | $4.47 | $24.84 |
| P/E Ratio | ★ $13.03 | $14.21 |
| Revenue Growth | 9.02 | ★ 31.19 |
| 52 Week Low | $100.31 | $47.50 |
| 52 Week High | $146.44 | $79.50 |
Technical Indicators
Market Signals| Indicator | CFR | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 60.54 |
| Support Level | $127.52 | $67.02 |
| Resistance Level | $129.17 | $69.48 |
| Average True Range (ATR) | 2.16 | 1.65 |
| MACD | -0.29 | 0.52 |
| Stochastic Oscillator | 50.87 | 97.15 |
Price Performance
Historical ComparisonAbout CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $53 billion in assets (as of September 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.